The ongoing coronavirus disease 2019 (COVID-19) pandemic, which has been caused by the rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly affected the ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The plasma D-dimer assay has been used, along with clinical prediction scores, to rule out ...

Use of clinical decision rules in conjunction with D-dimer thresholds adjusted higher based on either age or pretest probability is acceptably safe for ruling out acute pulmonary embolism (PE) without ...

The market expansion is primarily fueled by the increasing incidence of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood-clotting disorders worldwide.

What The Study Did: Researchers evaluated use of a blood test to rule out a blood clot in the lungs among patients hospitalized with COVID-19. Authors: Asa Oxner, M.D., of the University of South ...

Since its introduction to clinical use, the D-dimer test for deep venous thrombosis/pulmonary embolism has been a blessing and a curse. What is the current thinking regarding D-dimer use in clinical ...

Does an elevated ultrasensitive D-dimer level in a patient whose pre-test probability puts him at low risk for pulmonary embolus (PE) indicate an increased risk for PE or deep venous thrombosis (DVT)?

Venous thromboembolism (VTE) is a common disease that affects as many as 900,000 Americans yearly with an estimated 60,000 - 100,000 Americans dying each year as a result of VTE. D-Dimer levels ...